Haworth Innovative Therapeutics Clinic

Patients with small cell lung cancer, high risk neuroblastoma, sarcoma and malignant melanoma will be treated with a two-step radioimmunotherapy to assess safety and tolerability.

More information: https://clinicaltrials.gov/study/NCT05130255

This phase 3 trial compares the effect of open thoracic surgery to thoracoscopic surgery in treating patients with osteosarcoma that has spread to the lung. Open thoracic surgery is a type of surgery done through a single larger incision (like a large cut) that goes between the ribs, opens up the chest, and removes the cancer. Thoracoscopy is a type of chest surgery where the doctor makes several small incisions and uses a small camera to help with removing the cancer. This trial is being done to evaluate the two different surgery methods for patients with osteosarcoma that has spread to the lung to find out which is better.

More information: https://clinicaltrials.gov/study/NCT05235165?term=NCT05235165&rank=1

This phase 2/3 trial tests the safety, side effects, and best dose of a trial drug in combination with standard chemotherapy, and to compare the effect of adding a trial drug to standard chemotherapy alone in treating patients with newly diagnosed osteosarcoma.

More information: https://clinicaltrials.gov/study/NCT05691478?term=NCT05691478&rank=1

Patients with small cell lung cancer, high risk neuroblastoma, sarcoma and malignant melanoma will be treated with a two-step radioimmunotherapy, delivered as two separate products to assess safety and tolerability.

More information: https://clinicaltrials.gov/study/NCT05130255

This study is conducted in two phases. The phase 1 portion of the study evaluates the safety, tolerability, pharmacokinetics (PK), recommended phase 2 dose (RP2D), and effectiveness of lurbinectedin monotherapy in pediatric participants with previously treated solid tumors. This is followed by the phase 2 portion, to further assess the effectiveness and safety in pediatric and young adult participants with recurrent/refractory Ewing sarcoma.

More information: https://clinicaltrials.gov/study/NCT05734066

A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a randomized controlled trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for subjects with newly diagnosed high-risk neuroblastoma.

More information: https://clinicaltrials.gov/study/NCT02559778

DFMO will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral DFMO. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.

More information: https://clinicaltrials.gov/study/NCT02679144

Patients with small cell lung cancer, high risk neuroblastoma, sarcoma and malignant melanoma will be treated to assess safety and tolerability.

More information: https://clinicaltrials.gov/study/NCT05130255

This phase 3 trial tests how well the addition of a trial drug to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Adding a trial drug to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.

More information: https://clinicaltrials.gov/study/NCT06172296?term=NCT06172296&rank=1